I-Mab - ADR

NASDAQ:IMAB  
64.84
+2.76 (+4.45%)
Products

I-Mab And Abl Bio Receive US FDA Approval To Initiate Phase 1 Trial Of Bispecific Antibody Tj-Cd4b/Abl111 In Patients With Advanced Or Metastatic Solid Tumors

Published: 03/30/2021 13:32 GMT
I-Mab - ADR (IMAB) - I-mab and Abl Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody Tj-cd4b/abl111 in Patients With Advanced Or Metastatic Solid Tumors.